肝癌患者血清和组织中prohibitin的表达及其临床意义

肝脏 ›› 2016, Vol. 21 ›› Issue (11): 920-923.

肝癌患者血清和组织中prohibitin的表达及其临床意义

石娟娟, 杨宁, 吴凤萍, 杨颖, 李梅, 张欣, 贾晓黎, 尹佳锋, 党双锁

710004 西安交通大学第二附属医院感染科(石娟娟,杨宁,吴凤萍,杨颖,李梅,张欣,贾晓黎,党双锁),检验科(尹佳锋)

收稿日期:2016-08-12 出版日期:2016-11-30 发布日期:2020-06-12
通讯作者: 党双锁,Email:dang212@126.com
基金资助:
国家自然科学基金资助项目(31500650)

Clinical significances and expressions of prohibitin in patients with hepatocellular carcinoma

SHI Juan-juan, YANG Ning, WU Feng-ping, YANG Ying, LI Mei, ZHANG Xin, JIA Xiao-li, YIN Jia-feng, DANG Shuang-suo

Department of Infectious Diseases, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China

Received:2016-08-12 Online:2016-11-30 Published:2020-06-12
Contact: DANG Shuang-suo, Email: dang212@126.com

摘要/Abstract

摘要： 目的研究抑制素prohibitin(PHB)在肝癌患者血清和组织中的表达及其临床意义。方法应用双抗体夹心ELISA法检测肝癌患者和健康人各82例血清PHB浓度。应用RT-PCR和免疫组织化学的方法检测PHB在30例肝癌患者组织、癌旁组织和正常肝组织中的表达水平。同时,收集肝癌患者的临床资料,分析PHB表达与各临床参数之间的相关性。结果 PHB在肝癌患者和健康人血清中浓度分别为227.97 pg/mL和55.78 pg/mL,肝癌患者血清PHB浓度明显高于健康人(Z=-4.532,P=0.000);肝癌患者血清中的PHB浓度与ALT、TBil、AFP呈正相关(r=0.337,P=0.034;r=0.431,P=0.006;r=0.319,P=0.045)。在肝癌组织和癌旁组织中PHB蛋白阳性表达率分别为73.3%和86.7%,与正常肝组织(6.7%)比较,差异有统计学意义;在肝癌组织和癌旁组织中PHB mRNA的表达较正常组织亦明显升高;肝癌组织中PHB表达与肿瘤分化程度、TNM分期和AFP含量相关,即肿瘤低分化、TNM Ⅲ~Ⅳ期、AFP≥400 μg/L的肿瘤组织中PHB表达明显升高,差异有统计学意义。结论 PHB在肝癌患者血清和组织中均高表达,分别与肝脏损伤的程度和HCC恶性程度相关,提示PHB可能参与HCC的发生和发展。

关键词: 抑制素, 肝细胞性肝癌, 甲胎蛋白, 血清, 组织

Abstract: Objective To investigate serum and tissue expressions and the clinical significances of prohibitin in patients with hepatocellular carcinoma (HCC). Methods Serum PHB levels in 82 HCC patients and 82 healthy individuals were determined by ELISA assay. The expression of PHB in the 30 pairs of HCC tissues, paracancerous tissues and normal tissues were detected by real-time PCR and immunohistochemistry assay. The clinical data were collected to determine thecorrelation between PHB and clinical features. Results Serum PHB protein level in HCC patients was significantly increased when compared with healthy individuals group (227.97 vs. 55.78 pg/mL, Z= -4.532, P=0.000). The expression of PHB in HCC patients had positive correlation with alanine aminotransferase (ALT, r=0.337, P=0.034), total bilirubin (TBil, r=0.431, P=0.006) and AFP (r=0.319, P=0.045). The positive rate of PHB in HCC tissues and paracancerous tissues were 73.3% and 86.7% that were significantly higher thanthat of the normal tissues, respectively. The PHB mRNA expression in HCC tissues and paracancerous tissues were also higher than that of the normal tissues. The expression of PHB in HCC patients had correlation with differentiation grade, TNM stage and AFP. Conclusion PHB is overexpressed in HCC patients tissues and serum and correlated with the degree of liver injury and tumor malignancy, indicating that PHB may be involved in the occurrence and progression of HCC.

Key words: Prohibitin, Hepatocellular carcinoma, AFP, Serum, Tissue

石娟娟, 杨宁, 吴凤萍, 杨颖, 李梅, 张欣, 贾晓黎, 尹佳锋, 党双锁. 肝癌患者血清和组织中prohibitin的表达及其临床意义[J]. 肝脏, 2016, 21(11): 920-923.

SHI Juan-juan, YANG Ning, WU Feng-ping, YANG Ying, LI Mei, ZHANG Xin, JIA Xiao-li, YIN Jia-feng, DANG Shuang-suo. Clinical significances and expressions of prohibitin in patients with hepatocellular carcinoma[J]. Chinese Hepatolgy, 2016, 21(11): 920-923.

参考文献

[1] Rizwani W, Alexandrow M, Chellappan S. Prohibitin physically interacts with MCM proteins and inhibits mammalian DNA replication. Cell Cycle, 2009, 8: 1621-1629.
[2] Zhou TB, Qin Y. Signaling pathways of prohibitin and its role in diseases. J Recept Signal Transduct Res, 2013, 33:28-36.
[3] Ko KS, Tomasi ML, Iglesias-Ara A, et al. Liver-specific deletion of prohibitin 1 results in spontaneous liver injury, fibrosis, and hepatocellular carcinoma in mice. Hepatology, 2010, 52:2096-2108.
[4] Zhang Y, Chen Y, Qu C, et al. siRNA targeting prohibitins inhibits proliferation and promotes apoptosis of gastric carcinoma cell line SGC7901 in vitro and in vivo. Cell Mol Biol (Noisy-le-grand),2014, 60:26-32.
[5] Guan X, Liu Z, Wang L, et al. Identification of prohibitin and prohibiton as novel factors binding to the p53 induced gene 3 (PIG3) promoter (TGYCC)(15) motif. Biochem Biophys Res Commun, 2014, 443:1239-1244.
[6] Sato S, Murata A, Orihara T, et al. Marine natural product aurilide activates the OPA1-mediated apoptosis by binding to prohibitin. Chem Biol, 2011,18:131-139.
[7] Zhong N, Cui Y, Zhou X, et al. Identification of prohibitin 1 as a potential prognostic biomarker in human pancreatic carcinoma using modified aqueous two-phase partition system combined with 2D-MALDI-TOF-TOF-MS/MS. Tumour Bio, 2015,136:1221-1231.
[8] 党双锁,孙明珠,寻萌,等. 抑制素在人肝癌细胞SMMC-7721和Huh-7中的表达及其编码序列扩增. 中国肝脏病杂志(电子版), 2010, 2: 1-5.
[9] Diamond DL, Proll SC, Jacobs JM, et al. HepatoProteomics: applying proteomic technologies to the study of liver function and disease. Hepatology, 2006, 44:299-308.
[10] Sanchez-Quiles V, Santamaria E, Sequra V, et al. Prohibitin deficiency blocks proliferation and induces apoptosis in human hepatoma cells: molecular mechanisms and functional implications. Proteomics, 2010, 10:1609-1620.
[11] Xu Z, Wu J, Zha X. Up-regulation of prohibitin1 is involved in the proliferation of liver cancer cells. Sci China Life Sci, 2011, 54:121-127.
[12] Ren H, Du N, Liu G, et al. Analysis of variabilities of serum proteomic spectra in patients with gastric cancer before and after operation. World J Gastroenterol, 2006, 12: 2789-2792.
[13] Kang X, Zhang L, Sun J, et al. Prohibitin: a potential biomarker for tissue-based detection of gastric cancer. J Gastroenterol, 2008, 43: 618-625.

[1]	李永涛, 卜贤玉, 李滨. 替诺福韦酯补救治疗对HBV感染肝硬化患者的疗效分析[J]. 肝脏, 2020, 25(4): 400-402.
[2]	李飞, 郭振添, 莫海兴, 丁爱娇, 张拔山. 血清spHBV及PIVKA-Ⅱ联合检测对HBV所致肝癌的预测价值[J]. 肝脏, 2020, 25(4): 412-415.
[3]	冯文杏, 周小舟, 韩志毅, 孙新锋, 马文峰, 张卫. GALAD模型在诊断HBV相关肝细胞癌中的价值探讨[J]. 肝脏, 2020, 25(3): 291-294.
[4]	韦新焕, 张晶, 张卫, 柳雅立. 非活动性HBsAg携带者临床特征及自发性HBsAg血清学清除相关因素分析[J]. 肝脏, 2020, 25(2): 128-130.
[5]	陈攀丽, 唐建荣, 付雪芹, 张逸强, 胡景岚, 吴小力. Hp阳性监测在慢性乙型肝炎合并消化性溃疡患者中的临床意义[J]. 肝脏, 2020, 25(2): 184-185.
[6]	曹慧, 丁明, 赵凯. 自身免疫性肝炎患者血清腺苷脱氨酶水平与肝组织炎症活动的关系[J]. 肝脏, 2020, 25(1): 28-30.
[7]	孙艳华, 夏瑞雪, 王宁, 鲍越. AFP-L3、AFP、GP73、ALP联合检测对原发性肝癌的诊断价值研究[J]. 肝脏, 2020, 25(1): 63-65.
[8]	李祥苏, 金星星, 王冬冬, 吴旭东. 血清LECT2检测对肝细胞癌诊断的意义[J]. 肝脏, 2020, 25(1): 71-72.
[9]	左凌云, 张斌, 钱晶晶, 郁金红, 杨阳, 韦成. 自身免疫性肝炎患者血清高尔基体糖蛋白73的变化特征[J]. 肝脏, 2019, 24(9): 1053-1054.
[10]	符立贤, 林绍美. 非酒精性脂肪性肝炎发病的危险因素及血清Mac-2结合蛋白的诊断价值[J]. 肝脏, 2019, 24(9): 1074-1076.
[11]	宋洁, 邵雪, 贾胜男. 慢性乙型肝炎患者血清HBV DNA含量对IL-12诱导PBMC产生Th1/Th2类细胞因子协同效应的影响[J]. 肝脏, 2019, 24(8): 890-892.
[12]	何启军, 符火, 陈扬, 许海霞. 肝组织中程序性死亡受体1与自身免疫性肝炎炎性反应的关系[J]. 肝脏, 2019, 24(7): 756-760.
[13]	贾铭丽, 汪云. 血清淀粉样蛋白A联合腺苷脱氨酶在自身免疫性肝炎的价值分析[J]. 肝脏, 2019, 24(7): 773-776.
[14]	庞连胜, 赵万春. 血清CysC、尿β2-MG、尿mAlb三项联合检测对肝癌及肝硬化继发早期肾功能损伤的诊断价值[J]. 肝脏, 2019, 24(6): 649-652.
[15]	陈甜, 张烨琼, 吴艺锋. 小窝蛋白-1在肝癌细胞及间质中的表达及意义[J]. 肝脏, 2019, 24(6): 687-689.